Literature DB >> 22000793

Outcomes of T1b esophageal adenocarcinoma patients.

Jianmin Tian1, Ganapathy A Prasad, Lori S Lutzke, Jason T Lewis, Kenneth K Wang.   

Abstract

BACKGROUND: Esophagectomy is usually recommended for patients with submucosal esophageal adenocarcinoma (T1b EAC) because of the potential for lymph node metastasis (LNM). Endoscopic management often differs based on the risk of metastasis. There is limited information on the difference in outcomes for T1b-EAC with and without esophagectomy.
OBJECTIVES: To investigate (1) the outcomes of T1b EAC treatments with and without esophagectomy and (2) the percentage of LNM at esophagectomy for T1b-EAC.
DESIGN: Retrospective cohort.
SETTING: A tertiary Barrett's esophagus unit. PATIENTS: Sixty-eight T1b EAC patients based on EMR histology.
INTERVENTIONS: Esophagectomy and endoscopic therapies. MAIN OUTCOME MEASUREMENTS: Survival duration and mortality rate.
RESULTS: A total of 68 patients had T1b EAC; cumulative mortality rate was 30.9% and median survival duration was 39.5 months. Thirty-nine underwent esophagectomy and 29 did not. Among patients who underwent esophagectomy, 13 (33.3%) had LNM, and the mortality rate was 50.0% and 11.1% for those with and without LNM, respectively (P < .01). For those with and without esophagectomy, the cumulative mortality rates were 25.6% and 37.9%, and median survival duration was 48.9 and 34.8 months, respectively. There was no statistical difference in Charlson comorbidity index, number of EMRs, mortality rate, or survival duration. In Cox proportional hazard model analysis, the hazard ratio for esophagectomy was 0.5 (P = .21). LIMITATIONS: Retrospective, nonrandomized small sample size cohort.
CONCLUSION: Among the patients with T1b EAC found in EMR specimens who underwent esophagectomy, one third had regional LNM. In our small series, patients who underwent esophagectomy did not have a significantly different survival duration from that of those who did not, indicating that these patients may have similar outcomes [corrected].
Copyright © 2011 American Society for Gastrointestinal Endoscopy. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22000793     DOI: 10.1016/j.gie.2011.08.006

Source DB:  PubMed          Journal:  Gastrointest Endosc        ISSN: 0016-5107            Impact factor:   9.427


  9 in total

1.  Infiltration Depth is the Most Relevant Risk Factor for Overall Metastases in Early Esophageal Adenocarcinoma.

Authors:  Christina Oetzmann von Sochaczewski; Thomas Haist; Michael Pauthner; Markus Mann; Susanne Braun; Christian Ell; Dietmar Lorenz
Journal:  World J Surg       Date:  2020-04       Impact factor: 3.352

2.  The frequency of lymph node metastasis in early-stage adenocarcinoma of the esophagus with incipient submucosal invasion (pT1b sm1) depending on histological risk patterns.

Authors:  Hendrik Manner; Oliver Pech; Yvonne Heldmann; Andrea May; Michael Pauthner; Dietmar Lorenz; Annette Fisseler-Eckhoff; Manfred Stolte; Michael Vieth; Christian Ell
Journal:  Surg Endosc       Date:  2014-10-08       Impact factor: 4.584

3.  Expert pathology review and endoscopic mucosal resection alters the diagnosis of patients referred to undergo therapy for Barrett's esophagus.

Authors:  Katie Ayers; Chanjuan Shi; Kay Washington; Patrick Yachimski
Journal:  Surg Endosc       Date:  2013-02-07       Impact factor: 4.584

4.  Esophagectomy Following Endoscopic Resection of Submucosal Esophageal Cancer: a Highly Curative Procedure Even with Nodal Metastases.

Authors:  Daniela Molena; Francisco Schlottmann; Joshua A Boys; Shanda H Blackmon; Karen J Dickinson; Christy M Dunst; Wayne L Hofstetter; Michal J Lada; Brian E Louie; Benedetto Mungo; Thomas J Watson; Steven R DeMeester
Journal:  J Gastrointest Surg       Date:  2016-08-25       Impact factor: 3.452

5.  Surgery versus radical endotherapies for early cancer and high-grade dysplasia in Barrett's oesophagus.

Authors:  Cathy Bennett; Susi Green; John DeCaestecker; Max Almond; Hugh Barr; Pradeep Bhandari; Krish Ragunath; Rajvinder Singh; Janusz Jankowski
Journal:  Cochrane Database Syst Rev       Date:  2020-05-22

6.  Endoscopic mucosal resection or ablation for Barrett's esophagus containing high grade dysplasia: agreement strongest among expert gastroenterologists.

Authors:  Ashley Canipe; James Slaughter; Patrick Yachimski
Journal:  Endosc Int Open       Date:  2014-09-26

7.  Outcomes of submucosal (T1b) esophageal adenocarcinomas removed by endoscopic mucosal resection.

Authors:  Darren D Ballard; Neel Choksi; Jingmei Lin; Eun-Young Choi; B Joseph Elmunzer; Henry Appelman; Douglas K Rex; Hala Fatima; William Kessler; John M DeWitt
Journal:  World J Gastrointest Endosc       Date:  2016-12-16

8.  Chemoradiation as a nonsurgical treatment option for early-stage esophageal cancers: a retrospective cohort study.

Authors:  Ranjan Pathak; Maureen E Canavan; Samantha Walters; Michelle C Salazar; Daniel J Boffa
Journal:  J Thorac Dis       Date:  2021-01       Impact factor: 2.895

9.  Surgical vs Endoscopic Management of T1 Esophageal Adenocarcinoma: A Modeling Decision Analysis.

Authors:  Jacqueline N Chu; Jin Choi; Angela Tramontano; Christopher Morse; David Forcione; Norman S Nishioka; Julian A Abrams; Joel H Rubenstein; Chung Yin Kong; John M Inadomi; Chin Hur
Journal:  Clin Gastroenterol Hepatol       Date:  2017-11-24       Impact factor: 13.576

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.